Skip to main content
. Author manuscript; available in PMC: 2016 Mar 21.
Published in final edited form as: Invest New Drugs. 2009 Oct 29;29(1):63–72. doi: 10.1007/s10637-009-9335-4

Fig. 2.

Fig. 2

Effect of RKS262 [NSC-D-746733-1] on cell growth in a NCI60 cancer screen. A Cells were treated in 96-well plates with RKS262 (10 nM–10 µM) or vehicle and cell growth of the TCA fixed treated and untreated cells was assessed after 48 h with sulphorhodamine-B (SRB) solution and absorbance read at 515 nM. (For details see Supplementary Material, Online Resource 1). B Dose-dependent effect of RKS262 on ovarian cancer cell lines in the NCI60 screen